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Meta-analysisa b s t r a c t
Purpose: A population-based matched-pair comparison was performed to compare the efﬁcacy of stereo-
tactic body radiotherapy (SBRT) versus surgery for early-stage non-small cell lung cancer (NSCLC).
Methods: All the eligible studies were searched by PubMed, Medline, Embase, and the Cochrane Library.
The meta-analysis was performed to compare odds ratios (OR) for overall survival (OS), cancer-speciﬁc
survival (CSS), disease-free survival (DFS), local control (LC), and distant control (DC).
Results: Six studies containing 864 matched patients were included in the meta-analysis. The surgery
was associated with a better long-term OS in patients with early-stage NSCLC. The pooled OR and 95%
conﬁdence interval (CI) for 1-year, 3-year OS were 1.31 [0.90, 1.91] and 1.82 [1.38, 2.40], respectively.
However, the difference in 1-year and 3-year CSS, DFS, LC and DC was not signiﬁcant.
Conclusions: This systematic review found a superior 3-year OS after surgery compared with SBRT, which
supports the need to compare both treatments in large prospective, randomized, controlled clinical trials.
 2014 Elsevier Ireland Ltd. Radiotherapy and Oncology 112 (2014) 250–255 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Lung cancer is the ﬁrst and second leading cause of cancer death
in males and females, accounting for 13% of the total cases and 18%
of deaths in 2008 [1]. Surgery has become the recommended treat-
ment choice for patients diagnosed with early-stage non-small cell
lung cancer (NSCLC) [2], but many patients cannot undergo surgery
due to comorbidities or patient preference especially in the elderly
[3,4].
Stereotactic body radiotherapy (SBRT), more recently called
stereotactic ablative radiotherapy (SABR), is a novel non-invasive
radiation therapy modality and increasingly recognized as a favor-
able option in patients who are not considered operative candidates
for early stage lung cancer [5–8]. Few studies also described its
application in unresected hepatocellular carcinoma and benign
meningioma in the elderly patients [9,10]. This approach delivers
very high radiation doses to restricted tumor volumes using
focused beams guided by detailed imaging [11,12]. Previous studies
have revealed that SBRT could cause better survival and low rates of
toxicity than conventional fractionated radiotherapy [13]. Thegrowing evidence on SBRT outcomes has led to discussions on
whether it might be equally effective as surgery for medically ﬁt
patients with NSCLC.
Currently, no randomized trials comparing surgery versus SBRT
have been completed to date. The ACOSOG Z4099/Radiation
Therapy Oncology Group (RTOG) 1021 trial was a phase III ran-
domized prospective trial designed to compare outcomes in
high-risk patients with stage I lung cancer treated with sublobar
resection versus SBRT [14]. Unfortunately, this trial was recently
closed because of poor accrual. A systematic review has showed
that survival outcome in the short and medium term of patients
with stage I NSCLC treated with SABR is equivalent to surgery
[15]. Nevertheless, this study is an indirect comparison between
the two treatment approaches, and a direct comparison should
be a priority.
As far as we know, propensity score analysis allows for match-
ing across a range of baseline factors, generating two similar
groups for comparison. Therefore, we carried out a systematic
review of the current literature on the clinical outcomes of SBRT
for early-stage NSCLC, which mainly included propensity-matched
comparative study using a large cohort of patients undergoing
SBRT or surgical resection.
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Literature search
We searched PubMed, Medline, Embase, and the Cochrane
Library for studies published up to April 2014 by using the follow-
ing keywords relating to lung cancer, surgery, radiotherapy, SBRT,
and SABR.Selection criteria
Studies were considered eligible in the meta-analysis if they
met the following inclusion criteria: (1) all the patients included
were stage I lung cancers; (2) study designs were prospective
cohort studies or case-control studies; (3) providing data on over
survival (OS), cancer-speciﬁc survival (CSS), disease-free survival
(DFS), local control (LC) and (or) distant control (DC); (4) inter-
vention: SBRT or SABR; (5) control: surgery alone. Studies were
excluded based on the following reasons: (1) reviews, commen-
taries, editorials, case reports, and letters; (2) lacked key informa-
tion for calculation with methods developed by Parmar et al. [16],
Williamson et al. [17], and Tierney et al. [18]; (3) studies from
one author and reported repeated samples from the same
patients.Data extraction
Studies were extracted independently by two investigators.
Disagreements were resolved in consultation with a third investi-
gator. All relevant characteristics were collected including author,
publication year, country, study design, age, number of SBRT and
surgery patients, tumor stage, the dose and fraction of radiation
and survival outcome. The statistical data were extracted or calcu-
lated from the Kaplan–Meier survival curves. The primary end-
point of the study was the 1- and 3-year overall survival. In
addition, CSS, DFS, LC and DC were also compared. The main out-
comes were tabulated in 2  2 tables showing the number of
events and total patients from SBRT and surgery group described
by the previous research [19].Statistical analysis
Revman 5.1 software was downloaded from the Cochrane
Collaboration and used for our meta-analysis. Survival outcomes
were analyzed using odd ratios (OR) with 95% CI, which can be
extracted from the original article ﬁrstly. If not available, OR could
be generated according to the published data including number of
event patients and total patients from SBRT and surgery group.
When data were only available in the ﬁgures of studies, we read
the Kaplan–Meier curves by Engauge Digitizer version 4.1 and
extracted the survival data to calculate ORs and its 95% CI. An
observed OR >1 considered statistically signiﬁcant if the 95% CI
did not overlap 1 with p < 0.05.
The heterogeneity among studies was calculated using the X2
test with signiﬁcance deﬁned as p < 0.10, or quantiﬁed using I2
with a maximum value of 30% for low heterogeneity [20–24]. For
pP 0.10 or I2 6 50%, the ﬁxed-effects model (the Mantel–Haenszel
method) was used. If not, a random effect model (the DerSimonian
and Laird method) was used [24].
Begg’s test was used to assess the potential publication bias by
asymmetries in the funnel [25,26]. The calculation was performed
using STATA 11.0 (STATA Corporation, College Station, TX, USA),
p > 0.05 was considered that there was no potential publication
bias.Results
Search results and characteristics of studies
The systematic literature search identiﬁed a total of 1477
relevant references. After screening the titles and abstracts, we
excluded 199 duplicated and 1175 non-relevant studies. As shown
in Supplementary Fig. 1, 96 studies were further excluded for
observational study (n = 66), reviews (n = 23), insufﬁcient data
(n = 6), and duplicate data (n = 2). Finally, we identiﬁed six articles
in our meta-analysis [27–33].
A propensity-matched comparison was performed in the six
studies and a total of 864 matched patients were included in the
review. Patients were mainly matched using propensity scores
based on age, gender, tumor stage, pathology, Charlson comorbid-
ity score, lung function and performance score. Of these included
studies, 5 studies [27–31] used propensity score modeling and
matched for comorbidity. Comorbidity data were not available in
only one study by Palma et al. [32] where patients were matched
by age, tumor stage, gender, and treatment year. The characteris-
tics of included studies are listed in Table 1. All the patients in
the six studies were diagnosed with stage I NSCLC except for one
study a minority of stage II patients included [28]. The mean age
of all patients was 65 years and older. The range of doses in the
SBRT group was 32–60 Gy in 3–12 fractions. For patients undergo-
ing surgery, the main operation was lobectomy that 400 (92.6%)
underwent.Survival outcome
All the studies included presented Kaplan–Meier curves, num-
ber of events and total for 1-year, 3-year OS in 864 cases, of which
432 patients were treated with surgery, and 432 patients were
treated with SBRT. We compared OR for overall survival between
the two groups. The pooled OR and 95% CI by comparing the treat-
ment effect on 1-year and 3-year OS were 1.31 [0.90, 1.91] and
1.82 [1.38, 2.40] (Fig. 1), indicating that surgery was associated
with better long term survival outcomes in patients with early-
stage NSCLC. Three studies were noted in a sensitivity analysis con-
tributed to a better 3-year OS of surgery patients. Of these three
studies, Robinson et al. and Shirvani et al. reported the CSS data.
Patients treated with SBRT died from cancer at the same rate as
those undergoing surgery at 1-year (OR = 1; 95% CI 0.42–2.38;
P = 1.00) and 3-year (OR = 1.31; 95% CI 0.81–2.12; P = 0.27) (Fig. 2).
Only the studies by Crabtree et al. and Varlotto et al. reported
the DFS data. As shown in Fig. 3, there was no signiﬁcant difference
in the DFS. The combined OR (95% CI) for 1-year and 3-year DFS
was 1.11 [0.59,2.10] and 1.19 [0.71, 1.99], suggesting that no addi-
tional survival beneﬁt was derived from surgery in terms of DFS.Local control and distant control
Three studies representing 392 patients reported 1-year, 3-year
distant control, while two studies containing 264 patients for local
control. The pooled analysis showed that compared with SBRT, sur-
gery signiﬁcantly did not decline 1-year LC (OR = 0.59; 95% CI
0.14–2.52; P = 0.48) and 3-year LC (OR = 1.79; 95% CI 0.68–4.69;
P = 0.24) (Fig. 4). There was also no signiﬁcant difference in 1-year
DC (OR = 0.55; 95% CI 0.29–1.03; P = 0.06) and 3-year DC
(OR = 0.74; 95% CI 0.46–1.20; P = 0.22) (Fig. 5).Heterogeneity and publication bias
Heterogeneity was found in terms of 3-year DC (heterogeneity
v2 = 6.24, P = 0.04; I2 = 68%) and 3-year DFS (heterogeneity
Table 1
Main characteristics of all the included studies.
Author Year Country Study design Treatment No. of patients Male Mean age Radiation dose (Gy/#) Lobectomy (%)
Crabtree et al. 2014 USA Cohort study SBRT 56 29 70.7 45–60/3–6 78.6
Surgery 56 32 70
Varlotto et al. 2013 USA Cohort study SBRT 77 48–60/3–5 93.5
Surgery 77
Robinson et al. 2013 USA Cohort study SBRT 76 42 76 45–54/3–5 94.7
Surgery 76 26 65
Verstegen et al. 2013 Netherlands Cohort study SBRT 64 37 70.53 54–60/3–12 100
Surgery 64 36 67.95
Shirvani et al. 2012 USA Cohort study SBRT 99 59 78.1 100
Surgery 99 65 78.2
Palma et al. 2011 Canada Cohort study SBRT 60 40 79 32–60/3–8 81.7
Surgery 60 40 79
Fig. 1. Forest plot of the comparison between SBRT and surgery treatment for 1-year and 3-year OS.
252 A comparison of SBRT versus surgery for early stage NSCLCX2 = 4.01, P = 0.51; I2 = 75%) in the chi-square and I-square tests.
There was no evidence of heterogeneity in other survival out-
comes. Begg’s funnel plot was performed to assess the publication
bias in the overall survival. The funnel plot did not show any pub-
lication bias in 1-year OS (p = 0.573) and 3-year OS (p = 0.573)
(Supplementary Fig. 2). Since no more than 3 studies were
included in other survival outcomes of our study, Begg’s test and
funnel were not performed.
Discussion
National Comprehensive Cancer Network (NCCN) guidelines
have recommended surgery for patients able to have an operation
and conventionally radiation therapy or SBRT for patients medi-
cally inoperable [33]. Patients with NSCLC are frequently older
and experience a high burden of comorbid illness, so surgical
resection is often precluded. In patients who are unable to undergo
a surgical resection, conventional radiotherapy has been delivered
as an alternative therapy with poor long-term survival of 15–30%
and local failure of up to 50% [34–36]. Lately, a novel radiationtherapy modality called SBRT is increasingly being considered as
a preferred treatment choice in patients unﬁt for surgery or
patients at high-risk for postoperative complications [4,37]. To
date, no randomized trials comparing SBRT versus surgery have
been completed.
It is the ﬁrst propensity-matched comparative meta-analysis
revealing the efﬁcacy of SBRT in patients with early stage NSCLC
using surgery as the control. The results of our meta-analysis,
including data from six published studies with 864 patients, sug-
gests that SBRT and surgery will likely yield the same 1-year OS.
However, surgery was associated with a better 3-year OS in
patients with early-stage NSCLC. Thus, despite having worse OS
compared with surgery, patients treated with SBRT died from can-
cer at the same rate as those undergoing surgery, indicating that
SBRT patients may be less healthy and many died of non-cancer
causes. In addition, there was no signiﬁcant difference in the
1-year and 3-year DFS, LC, and DC in such patients.
Treatment-related toxicity is an important factor in evaluating
therapy. Only two studies by Robinson et al. and Verstegen et al.
reported the data. Overall patterns and degrees of toxicity were
Fig. 2. Forest plot of the comparison between SBRT and surgery treatment for 1-year and 3-year CSS.
Fig. 3. Forest plot of the comparison between SBRT and surgery treatment for 1-year and 3-year DFS.
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with SBRT, toxicity often consisted of esophagitis, pneumonitis,
hemoptysis, chest-wall pain, and no deaths were attributed to
SBRT. For the other, cardiovascular and pulmonary complications
were very common, including arrhythmia, myocardial infarction,
pneumonia, thoracic empyema, and severe lung hemorrhage. The
data as captured in individual studies do not cater for easy compar-
ison, and may miss functional consequences of the various treat-
ment approaches.
There are still several limitations in our study. First of all, only
observational studies on SBRT for early stage NSCLC have been
published, and most are retrospective or prospective Phase I–II
studies. Although, we did a propensity score analysis allows for
matching across a broad range of baseline factors, such as age,
sex, tumor size, pathology, tumor location, and so on, creating
two similar groups for comparison. Propensity score matching is
still imperfect and cannot check for all biases, including confound-
ing by indication [38]. There are still inevitably limitations to the
ability of such an analysis no matter how carefully done. Only ran-
domized comparisons between surgery and SBRT will avoid theimbalances and selection biases present in these comparisons. Sec-
ondly, the radiation dose and fractionation of SBRT mostly
depended on the investigator’s experience and varied because of
a deﬁciency of biologically effective dose (BED) guideline. A system
review and meta-analysis by Zhang et al. reported that the OS for
the medium or medium to high BED (range, 83.2–146 Gy) groups
were higher than those for the low or high BED group for SBRT
in Stage I NSCLC [39]. Kestin et al. recently reported that a substan-
tial dose–response relationship for local control of NSCLC following
image-guided SBRT with optimal PTV (mean) BED10 > 125 Gy [40].
Thirdly, the individualized treatment planning is not the same,
including rigorous accounting for organ motion, such as breath
hold techniques, abdominal compression, and the acquisition of
three and four dimensional (4D) planning CT scan. Patients with
large tumor motion often have large margins to account for geo-
metric uncertainty, resulting in an increased exposure of normal
tissue to high doses. The latest research by Peulen et al. reported
that mid-ventilation (MidV) based Planning Target Volumes
(PTV) margins typically lead to smaller treatment volumes in SBRT
[41]. In addition, the operation method was very diverse, including
Fig. 4. Forest plot of the comparison between SBRT and surgery treatment for 1-year and 3-year LC.
Fig. 5. Forest plot of the comparison between SBRT and surgery treatment for 1-year and 3-year DC.
254 A comparison of SBRT versus surgery for early stage NSCLClobectomy, segmentectomy, video-assisted thoracoscopic surgery
(VATS) lobectomy, and pneumonectomy, which may affect the out-
come of the comparison.
In summary, patients with early stage NSCLC treated with SBRT
had similar DFS, LC and DC as patients treated with surgery but
worse 3-year OS on a matched-pair analysis. However, we found
two studies giving the signiﬁcant impact on the long term survival
after a sensitivity analysis conducted, in which patients treated
with SBRT died from cancer at the same rate as those undergoing
surgery. At present, a suggestion about SBRT or surgery might be
best made at patient performance status, economic condition,
comorbidity, operative mortality risk, quality of life, and patient
preference. Our results support the need to enroll patients on large
prospective, randomized controlled trials to accurately compare
outcomes between SBRT and surgical operation for early stage
NSCLC.Conﬂict of interest
There were no conﬂicts of interest associated with this work for
any of the authors.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2014.08.
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